AU2012203095B2 - DAC HYP compositions and methods - Google Patents

DAC HYP compositions and methods Download PDF

Info

Publication number
AU2012203095B2
AU2012203095B2 AU2012203095A AU2012203095A AU2012203095B2 AU 2012203095 B2 AU2012203095 B2 AU 2012203095B2 AU 2012203095 A AU2012203095 A AU 2012203095A AU 2012203095 A AU2012203095 A AU 2012203095A AU 2012203095 B2 AU2012203095 B2 AU 2012203095B2
Authority
AU
Australia
Prior art keywords
daclizumab
peak
composition
auc
dac hyp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012203095A
Other languages
English (en)
Other versions
AU2012203095A1 (en
Inventor
John W. Burky
Taymar Hartman
Ping Y. Huang
Braeden Partridge
Thomas J. Robinson
Paul W. Sauer
J. Yun Tso
Mark C. Wesson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Biotechnology Ltd
Original Assignee
AbbVie Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Biotechnology Ltd filed Critical AbbVie Biotechnology Ltd
Publication of AU2012203095A1 publication Critical patent/AU2012203095A1/en
Assigned to ABBVIE BIOTHERAPEUTICS INC. reassignment ABBVIE BIOTHERAPEUTICS INC. Amend patent request/document other than specification (104) Assignors: ABBOTT BIOTHERAPEUTICS CORP.
Assigned to ABBVIE BIOTECHNOLOGY LTD reassignment ABBVIE BIOTECHNOLOGY LTD Request for Assignment Assignors: ABBVIE BIOTHERAPEUTICS INC.
Application granted granted Critical
Publication of AU2012203095B2 publication Critical patent/AU2012203095B2/en
Priority to AU2016202873A priority Critical patent/AU2016202873B2/en
Priority to AU2018200654A priority patent/AU2018200654A1/en
Priority to AU2020202298A priority patent/AU2020202298A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012203095A 2011-05-27 2012-05-25 DAC HYP compositions and methods Ceased AU2012203095B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2016202873A AU2016202873B2 (en) 2011-05-27 2016-05-04 DAC HYP compositions and methods
AU2018200654A AU2018200654A1 (en) 2011-05-27 2018-01-29 DAC HYP compositions and methods
AU2020202298A AU2020202298A1 (en) 2011-05-27 2020-03-31 DAC HYP compositions and methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161490998P 2011-05-27 2011-05-27
US61/490,998 2011-05-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016202873A Division AU2016202873B2 (en) 2011-05-27 2016-05-04 DAC HYP compositions and methods

Publications (2)

Publication Number Publication Date
AU2012203095A1 AU2012203095A1 (en) 2012-12-13
AU2012203095B2 true AU2012203095B2 (en) 2016-02-04

Family

ID=46177353

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2012203095A Ceased AU2012203095B2 (en) 2011-05-27 2012-05-25 DAC HYP compositions and methods
AU2016202873A Ceased AU2016202873B2 (en) 2011-05-27 2016-05-04 DAC HYP compositions and methods
AU2018200654A Abandoned AU2018200654A1 (en) 2011-05-27 2018-01-29 DAC HYP compositions and methods
AU2020202298A Abandoned AU2020202298A1 (en) 2011-05-27 2020-03-31 DAC HYP compositions and methods

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2016202873A Ceased AU2016202873B2 (en) 2011-05-27 2016-05-04 DAC HYP compositions and methods
AU2018200654A Abandoned AU2018200654A1 (en) 2011-05-27 2018-01-29 DAC HYP compositions and methods
AU2020202298A Abandoned AU2020202298A1 (en) 2011-05-27 2020-03-31 DAC HYP compositions and methods

Country Status (10)

Country Link
US (7) US20120301429A1 (enExample)
EP (1) EP2527429A3 (enExample)
JP (4) JP6055615B2 (enExample)
CN (2) CN102796705A (enExample)
AU (4) AU2012203095B2 (enExample)
BR (1) BR102012012673A8 (enExample)
CA (1) CA2777978A1 (enExample)
MX (1) MX339533B (enExample)
RU (2) RU2661764C2 (enExample)
SG (1) SG185920A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2777978A1 (en) 2011-05-27 2012-11-27 Abbott Biotherapeutics Corp. Dac hyp compositions and methods
WO2013022972A1 (en) * 2011-08-08 2013-02-14 Abbott Biotherapeutics Corporation Methods of treating progressive forms of multiple sclerosis
US20140295497A1 (en) * 2011-11-30 2014-10-02 Taymar E. Hartman Vectors and host cells comprising a modified sv40 promoter for protein expression
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2015034566A1 (en) * 2013-09-04 2015-03-12 Emd Millipore Corporation Protein a chromatography
GB201503578D0 (en) * 2015-03-03 2015-04-15 Ge Healthcare Bio Sciences Ab Sanitization method for affinity chromatography matrices
WO2016154290A1 (en) * 2015-03-23 2016-09-29 Alexion Pharmaceuticals, Inc. Virus filtration
MX383558B (es) * 2015-08-12 2025-03-14 Pfizer Cisteinas de anticuerpo con capuchon y sin capuchon y su uso en conjugacion de anticuerpo-farmaco
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
WO2017132376A1 (en) 2016-01-27 2017-08-03 Just Biotherapeutics, Inc. Hybrid promoter and uses thereof
WO2018027195A1 (en) 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
JP7479151B2 (ja) * 2017-01-30 2024-05-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド クロマトグラフィーにおけるバイオバーデンを低減するための組成物および方法
JP7786876B2 (ja) * 2017-12-21 2025-12-16 ジェンザイム・コーポレーション プロテインａクロマトグラフィー中の不純物の除去を促進する方法
EP3956046A1 (en) * 2019-04-17 2022-02-23 Bristol-Myers Squibb Company Methods for regenerating chromatography resins
KR102731889B1 (ko) * 2019-07-18 2024-11-19 에이비온 주식회사 2당화된 인터페론-베타 단백질의 정제 방법
US20220259261A1 (en) * 2019-08-01 2022-08-18 Regeneron Pharmaceuticals, Inc. Method for viral inactivation
KR20240007293A (ko) 2019-12-06 2024-01-16 리제너론 파아마슈티컬스, 인크. 항-vegf 단백질 조성물 및 이를 생산하는 방법
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
JP7631742B2 (ja) * 2020-11-10 2025-02-19 東ソー株式会社 ペプチド性リガンド固定化カラムの洗浄方法
KR20240004718A (ko) * 2021-05-03 2024-01-11 베링거 인겔하임 인터내셔날 게엠베하 스페솔리맙의 제조방법
CN114181300A (zh) * 2021-12-20 2022-03-15 方坦思(上海)生物医药有限公司 一种高纯度单克隆抗体的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1430566A (en) * 1974-11-15 1976-03-31 Nestel Sa Isolation of proteins
US7442777B2 (en) * 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
RU2318537C2 (ru) * 2001-04-06 2008-03-10 Юниверсити Оф Бристоль Применение cd25-связывающих молекул для лечения пациентов, устойчивых к стероидам
JP2005325133A (ja) * 2001-10-15 2005-11-24 Kirin Brewery Co Ltd 抗ｈｌａ−ｄｒ抗体の利用
US20040002135A1 (en) * 2002-03-28 2004-01-01 Sauer Paul W. Adapted NS0 cell lines with the ability to grow under glutamine-free conditions
US7365168B2 (en) * 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JPWO2004087761A1 (ja) * 2003-03-31 2006-07-27 麒麟麦酒株式会社 ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
EP2035034A4 (en) 2006-06-09 2009-11-18 Univ Maryland GLYCOSYLATION-CONTROLLED ANTIBODY THERAPY
JP2010510963A (ja) * 2006-06-14 2010-04-08 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー セラミックヒドロキシアパタイトを使用する抗体の精製方法
US20090209656A1 (en) * 2006-07-06 2009-08-20 Ge Healthcare Bio-Sciences Ab Disinfection/sanitation method where the material is treated with a solution comprising benzyl alcohol and c2-3 alcohol
EP2271669A1 (en) * 2008-03-11 2011-01-12 Genentech, Inc. Antibodies with enhanced adcc function
RU2011111391A (ru) * 2008-08-28 2012-10-10 Эбботт Байотерапьютикс Корп. (Us) Способ лечения пациентов, страдающих рассеянным склерозом, антителами анти-il2r
WO2010138502A2 (en) * 2009-05-26 2010-12-02 Momenta Pharmaceuticals, Inc. Production of glycoproteins
US20120277165A1 (en) 2009-06-05 2012-11-01 Collins Brian E Methods of modulating fucosylation of glycoproteins
ES2817802T3 (es) * 2009-08-07 2021-04-08 Emd Millipore Corp Métodos para purificar una proteína objetivo de una o más impurezas en una muestra
WO2011019622A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
US10087236B2 (en) * 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
PT2542590T (pt) 2010-03-05 2017-08-31 Univ Johns Hopkins Composições e métodos para anticorpos e proteínas de fusão imunomoduladores direcionados
CA2777978A1 (en) * 2011-05-27 2012-11-27 Abbott Biotherapeutics Corp. Dac hyp compositions and methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BURKY, J. E. et al., Biotechnology and Bioengineering, 2007, vol. 96, no. 2, pages 281-293 *
HARTMAN, T. E. et al., Biotechnology and Bioengineering, 2007, vol. 96, no. 2, pages 294-306 *
ZHU, Y. et al., Biotechnology and Bioengineering, 2008, vol 101, no. 4, pages 751-760 *

Also Published As

Publication number Publication date
EP2527429A2 (en) 2012-11-28
JP2012244993A (ja) 2012-12-13
US20150203583A1 (en) 2015-07-23
AU2016202873A1 (en) 2016-05-26
MX2012006115A (es) 2012-12-04
RU2012121876A (ru) 2013-11-27
US20180127506A1 (en) 2018-05-10
BR102012012673A8 (pt) 2021-02-17
US20150274832A1 (en) 2015-10-01
BR102012012673A2 (pt) 2015-11-17
CA2777978A1 (en) 2012-11-27
US20170247461A1 (en) 2017-08-31
EP2527429A3 (en) 2013-10-30
US20120301429A1 (en) 2012-11-29
JP2016210796A (ja) 2016-12-15
CN107090040A (zh) 2017-08-25
US20200157230A1 (en) 2020-05-21
JP2020078348A (ja) 2020-05-28
AU2012203095A1 (en) 2012-12-13
JP2018134091A (ja) 2018-08-30
CN102796705A (zh) 2012-11-28
US20150197573A1 (en) 2015-07-16
AU2016202873B2 (en) 2018-02-22
AU2018200654A1 (en) 2018-02-15
MX339533B (es) 2016-05-30
US9260528B2 (en) 2016-02-16
US9815903B2 (en) 2017-11-14
US9340619B2 (en) 2016-05-17
US9676860B2 (en) 2017-06-13
SG185920A1 (en) 2012-12-28
JP6055615B2 (ja) 2016-12-27
RU2018119112A (ru) 2018-11-07
RU2661764C2 (ru) 2018-07-19
AU2020202298A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
US9815903B2 (en) DAC HYP compositions
US20180127507A1 (en) Methods of treating progressive forms of multiple sclerosis
JP7507160B2 (ja) ヒトｔｒｂｖ９に特異的に結合するモノクローナル抗体
TW201302791A (zh) 抗ｐｓｇｌ－１抗體及其之應用
US20260035465A1 (en) Pharmaceutical compositions of programmed death receptor 1 (pd-1) antibodies and ph20 variants or fragments thereof
US20250064889A1 (en) Trpv6 inhibitors and combination therapies for treating cancers
US20260034211A1 (en) PHARMACEUTICAL COMPOSITIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND rHuPH20 OR VARIANTS OR FRAGMENTS THEREOF
TW202216779A (zh) 治療性抗體類和彼等之用途
CN101460522A (zh) 糖基化抗体
HK1178205A (en) Dac hyp compositions and methods
US20220356248A1 (en) Antibodies specific to glycosylated lag3 and methods of use thereof
KR20260070302A (ko) 글리코엔지니어링된 항-cd20 항체
HK1262523A1 (en) Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ABBVIE BIOTECHNOLOGY LTD

Free format text: FORMER APPLICANT(S): ABBVIE BIOTHERAPEUTICS INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired